Oral Solution 100ml
Composition Per 5ml of solution
Cyproheptadine orotate 1.5 mg
Carnitine chlorhydrate 150 mg
Lysine chlorhydrate 150 mg
Vitamin B1 10 mg
Vitamin B6 10 mg
Vitamin B12 100mg
Coenzyme B12 --
Excipients, s.q. (Containing 2.5mg of saccharine sodique and 75mg of ethanol)
Pharmaceutical forms and contents
Solution for oral use. Bottles of 100 ml.
components making up the formula of Tres-orix Forte, constitute for the
first time the ideal pharmacological response to a clinical problem of
such frequency and such social repercussions as is the loss of appetite,
motivated by many causes both organic as well as psychological.
Cyproheptadine orotate, of original Prodes synthesis, by acting
selectively on the hypothalamic centre of the appetite, starts up the
neurovegetative mechanisms which diminish the “fullness threshold”, at
the same time lacking side effects on account of its in being in the
form of an orotic salt.
In Tres-orix Forte, two aminoacids, already
well experimented and with excellent results, are added to this
orexigenic drug. Carnitine chlorhydrate on account of its positive
action on weight gain and lysine chlorhydrate on account of being one of
the aminoacids which cannot be synthesized by the organism and which is
the great supplier of the fundamental amino groups for the metabolism,
such action also being reinforced by the presence of the vitamins of the
B group, of well-known tonic and energizing properties.
in children and adolescent, whether of and organic or
emotional-psychological cause post infections anorexia. Deficiency
anorexia. Retardation in growth. Anorexia of the infant, Habitual
vomiting(excluding when of an organic origin). Emotional instability
when accompanied by anorexic crises. Anorexia of the adult
Hypersensivity to the components, Glaucoma, Predisposition to urine retention, Newborns.
Tres-orix Forte should not be administered simultaneously with other medicines which are Central Nervous System depressors.
Warnings on Excipients
Tres-Orix Forte Oral Solution:
contains ethanol as excipient, which can be cause of risk in patients
with hepatic disease, alcoholism, epilepsy and in pregnant women and
Dosage and administration
a) Capsules: One before each of main meals(3/day).
b) Oral solution: Two teaspoonfuls of 5 ml before breakfast, lunch, and dinner.
Infants: Two teaspoonfuls of 2.5 ml daily, distributed in two intakes.
to 7 to 12 years old: One teaspoonful of 5 ml before breakfast, lunch,
and dinner, or one capsule before breakfast and one before dinner(2
These doses are approximate, indicative doses, as it is known
that responses to the preparations of this group are different according
to individual idiosyncrasies of each patient. This appearance of
drowsiness is a good sign for calculating the dosage and is even
desirable it slightly appears in nervous children because their psychic
condition improves simultaneously. However, drowsiness tends to
disappear a few days after treatment is begun.
The effects of
treatment are usually observed between 4 and 10 days after
administration is initiated. Treatment can be administered for periods
of one or two months with rest periods of 15 days to 1 month, without
any undesirable side effect having been noticed nor any alteration of
the humoral constants.
therapeutic doses, there is no risk of intoxication. In the event of a
massive accidental ingestion, the patient should be kept under strict
observation and symptomatic measures should be taken.
In adults drowsiness can occur, for which reason cautions is recommended in driving or in performing tasks requiring alertness.
If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.
Do not use this drug after the expiry date given on the package.
Neither all presentations nor all pharmaceutical forms are available in all markets
Under medical prescription
Keep out of the reach of children